Celonic Inaugurates “Next Generation” Biologics Development Center (BDC) and Pilot Plant in Basel, Switzerland

Reducing the cost and risks of scaling-up biologic medicine production

20-Jun-2024 - TheCelonic Group, a Swiss Based Quality Biologics Contract Development and Manufacturing Organization (CDMO) today opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland. This laboratory expansion will help pharmaceutical companies develop and optimize ...

Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies

Ikarovec is developing novel gene therapies to treat serious, but common eye diseases

06-Jun-2023 - Rentschler Biopharma SE and Ikarovec, which is developing novel multicistronic gene therapies to treat major ophthalmic indications, announced that the two companies have entered into a collaboration. Under the agreement, Rentschler Biopharma’s ATMP site in Stevenage, UK, will support the ...

Gene activity in a test tube

An accurate picture of gene activity can provide the key to the development of new, targeted therapies

18-Oct-2022 - When searching for the causes of illnesses and developing new treatments, it is absolutely vital to have a precise understanding of the genetic fundamentals. Würzburg researchers have devised a new technique for this purpose. Pathological processes are usually characterised by altered gene ...

Siemens and Zeta drive forward the digital transformation of pharmaceutical processes worldwide

Strategic partnership

04-Nov-2020 - Siemens and Zeta have entered into a strategic partnership. The aim of both companies is to drive forward the digital transformation of pharmaceutical processes worldwide. Zeta, a specialist with many years of experience in major projects for the biopharmaceutical industry, takes the role of the ...

Lonza to Establish Strategic Biomanufacturing Base in China

13-Dec-2018 - Lonza announced an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou (CN). As the facility is part of a larger biomanufacturing initiative between GE Healthcare and Guangzhou Development District (GDD), the agreement will be finalized ...

Abzena invests in expansion of biotherapeutics and makes executive appointment

07-Nov-2018 - Dr. Jonathan Goldman, CEO, announced that Abzena has augmented existing 500 L scale biologics equipment with $20M of investment into two new manufacturing suites at 500 L and 2000 L scale in a new GMP facility in San Diego, which will be equipped with Sartorius single use bioreactors. Abzena’s ...

ProBioGen and Pionyr Immunotherapeutics initiate second collaboration

Collaboration in contract development and manufacturing

11-Jul-2018 - ProBioGen AG, a premier service and technology provider for complex therapeutic glycoproteins, andPionyr Immunotherapeutics, an immuno-oncology company which develops next generation antibody-based therapeutics that target the tumor microenvironment, today announced a second service and license ...

Successful ACHEMA closes in Frankfurt

15-Jun-2018 - At the trade show for the process industry, more than 3,700 exhibitors from 55 countries showcased the latest equipment and innovative processes for the chemical, pharma and food industry. Whether in the classic process technology hall, the pump exhibition or in the plant engineering section, ...

Reaction calorimetry in microreactors

12-Jun-2018 - At Achema 2018 the Fraunhofer Institute for Chemical Technology will demonstrate the latest gen-eration of continuous reaction calorimeters. These permit rapid screening of thermokinetic data, making kinetic constants and safety-relevant data available in the early stages of process ...

Merck and Samsung BioLogics to Extend Strategic Alliance

02-Nov-2017 - Merck announced the signing of a Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologics process development. The alliance would accelerate process development and clinical material production at small biotech start-ups ...